Free Access
| Issue |
Med Sci (Paris)
Volume 41, Number 2, Février 2025
Nos jeunes pousses ont du talent !
|
|
|---|---|---|
| Page(s) | 191 - 194 | |
| Section | Partenariat médecine/sciences - Écoles doctorales - Masters | |
| DOI | https://doi.org/10.1051/medsci/2025018 | |
| Published online | 03 March 2025 | |
- Campbell GL, Marfin AA, Lanciotti RS, et al. West Nile virus. Lancet Infect Dis 2002 ; 2 : 519–29. [CrossRef] [PubMed] [Google Scholar]
- Petersen LR, Brault AC, Nasci RS. West Nile virus : review of the literature. JAMA 2013 ; 310 : 308–15. [CrossRef] [PubMed] [Google Scholar]
- Sewgobind S, McCracken F, Schilling M. JMM Profile : West Nile virus. J Med Microbiol 2023 ; 72 : 001730. [CrossRef] [Google Scholar]
- Santini M, Haberle S, Židovec-Lepej S, et al. Severe West Nile Virus neuroinvasive disease : clinical characteristics, short- and long-term outcomes. Pathogens 2022 ; 11:52. [CrossRef] [PubMed] [Google Scholar]
- Lim SM, Koraka P, Osterhaus ADME, Martina BEE. West Nile virus : immunity and pathogenesis. Viruses 2011 ; 3 : 811–28. [CrossRef] [PubMed] [Google Scholar]
- Sutinen J, Fell DB, Sander B, Kulkarni MA. Comorbid conditions as risk factors for West Nile neuroinvasive disease in Ontario, Canada : a population-based cohort study. Epidemiol Infect 2022 ; 150 : e103. [CrossRef] [PubMed] [Google Scholar]
- Lindsey NP, Staples JE, Lehman JA, Fischer M. Medical risk factors for severe West Nile virus disease, United States, 2008-2010. Am J Trop Med Hyg 2012 ; 87 : 179–84. [CrossRef] [PubMed] [Google Scholar]
- Beasley DWC, Li L, Suderman MT, Barrett ADT. Mouse neuroinvasive phenotype of West Nile virus strains varies depending upon virus genotype. Virology 2002 ; 296 : 17–23. [CrossRef] [Google Scholar]
- Bastard P, Gervais A, Le Voyer T, et al. Autoantibodies neutralizing type I IFNs are present in ~4 % of uninfected individuals over 70 years old and account for ~20 % of COVID-19 deaths. Sci Immunol 2021 ; 6 : eabl4340. [CrossRef] [PubMed] [Google Scholar]
- Zhang Q, Pizzorno A, Miorin L, et al. Autoantibodies against type I IFNs in patients with critical influenza pneumonia. J Exp Med 2022219e20220514. [Google Scholar]
- Alotaibi F, Alharbi NK, Rosen LB, et al. Type I interferon autoantibodies in hospitalized patients with Middle East respiratory syndrome and association with outcomes and treatment effect of interferon beta-1β in MIRACLE clinical trial. Influenza Other Respir Viruses 2023 ; 17 : e13116. [CrossRef] [PubMed] [Google Scholar]
- Gervais A, Rovida F, Avanzini MA, et al. Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in ∼ 40 % of patients. J Exp Med 2023 ; 220 : e20230661. [CrossRef] [PubMed] [Google Scholar]
- Bastard P, Michailidis E, Hoffmann H-H, et al. Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine. J Exp Med 2021 ; 218 : e20202486. [CrossRef] [PubMed] [Google Scholar]
- Mieli-Vergani G, Bansal S, Daniel JF, et al. Peginterferon alfa-2a (40KD) plus lamivudine or entecavir in children with immune-tolerant chronic hepatitis B. J Pediatr Gastroenterol Nutr 2021 ; 73 : 156–60. [CrossRef] [PubMed] [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.